ONI Names Sharon Krumm, PhD, RN, Editor of Oncology Nursing

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 10
Volume 10
Issue 10

MELVILLE, New York-The publishers of ONI are pleased to announce that Sharon K. Krumm, PhD, RN, will serve as Editor of Oncology Nursing. Dr. Krumm earned her bachelor of science in nursing from the University of Missouri School of Nursing, Columbia, and her MS and PhD from the University of Missouri.

MELVILLE, New York—The publishers of ONI are pleased to announce that Sharon K. Krumm, PhD, RN, will serve as Editor of Oncology Nursing. Dr. Krumm earned her bachelor of science in nursing from the University of Missouri School of Nursing, Columbia, and her MS and PhD from the University of Missouri.

Since 1996, she has been administrator and director of nursing at The Johns Hopkins Oncology Center, Baltimore. She is also assistant professor at The Johns Hopkins University Schools of Medicine and Nursing. Previously, she was director of nursing at the University of Missouri, Ellis Fischel Cancer Center. She joined Johns Hopkins in 1988 as director of nursing.

Dr. Krumm serves on the Board of Trustees of the American Cancer Society Mid-Atlantic Division. She has extensive research experience and is currently principal investigator for a study evaluating Johns Hopkins’ inpatient/outpatient care continuum program. She is the author, coauthor, or editor of 30 journal articles or abstracts and seven books.

Dr. Krumm brings to ONI a wealth of knowledge in the oncology nursing field and will be actively involved in selecting material specifically of interest to oncology nurses.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content